1

Palo Alto, California

Consultant

Present

2

Los Angeles, California

Member, Advisory Team

Present

3

Tucson, Arizona

Member, Board of Directors (unpaid)

Present

4

Rochester, Minnesota

Member, Scientific Advisory Committee, Cardiovascular Research Center

Present

5

Cambridge, Massachusetts

Member, Nominating & Corporate Governance Committee of the Board of Directors

Present

6

Cambridge, Massachusetts

Member, Board of Directors

Present

7

Raleigh, North Carolina

Member, Board of Directors (unpaid)

Present

8

Columbus, Ohio

Member, Clinical Advisory Board (unpaid)

Present

9

Charleston, South Carolina

Member, Advisory Board, South Carolina Clinical & Translational Science Institute

Present

10

Nashville, Tennessee

Member, Biomedical Science Advisory Board, Office of Research

Present

1

Medical University of South Carolina

Charitable Donations Made on My Behalf

$1,000

2

Vanderbilt University Medical Center

Advisory Board Fees

$5,000

3

University of Colorado

Advisory Board Fees

$2,000

4

Centessa Pharmaceuticals, PLC

Board of Directors Fees

$20,826

5

Centessa Pharmaceuticals, PLC

Committee Fees

$563

6

Centessa Pharmaceuticals, PLC, director fees: cash receivable

$1,001 - $15,000

None (or less than $201)

7

Centessa Pharmaceuticals, PLC, committee fees: cash receivable

$1,001 - $15,000

None (or less than $201)

8

Centessa Pharmaceuticals, PLC, unvested stock options

$1,000,001 - $5,000,000

None (or less than $201)

9

Clinetic, Inc. (health software & technology solutions), vested stock options

$15,001 - $50,000

None (or less than $201)

10

Cytokinetics, Inc.

Board of Directors Fees

$41,299

1

Los Angeles, California

Pursuant to the terms of my agreement with the company, should I participate in the advisory team meeting scheduled for December 2021, I am entitled to receive unvested stock options in the company. I will forfeit my unvested stock options upon resignation.

6/2021

2

Cambridge, Massachusetts

Pursuant to my agreement with the company, I am entitled to receive any outstanding board of director’s fees and committee fees pro-rated through the date of my resignation. The company will make these payments to me in the month following the end of the quarter. Additionally, and pursuant to the terms of the companies Amended and Restated Stock Option Incentive Plan, the Administrator of the company is authorized to and has agreed to accelerate the vesting of my unvested stock options that vest prior to February 19, 2022. After February 19, 2022, my options vest on a monthly basis. Any remaining unvested options will be forfeited upon resignation. Pursuant to the terms of the plan, I have 90 days to exercise my vested options.

1/2021

3

South San Francisco, California

Pursuant to the terms of the 2004 Equity Incentive Plan & 2004 Option Agreement and the Amended & Restated 2004 Equity Incentive Plan, upon my resignation from the company I will forfeit my unvested restricted stock units and my unvested stock options. I am entitled to retain my shares of common stock and vested stock options.

2/2018

4

Raleigh, North Carolina

I currently hold vested company stock options. I will forfeit my stock options upon resignation.

10/2017

5

South San Francisco, California

I own unvested Verily Award Units. I also own Verily Employee Units, representing an equity ownership interest in the company. Under the Verily Life Sciences, LLC, Value Creation Award Plan, when the Verily Award Units vest, they are settled in Employee Units. As is consistent with the terms of the Verily Life Sciences, LLC, Value Creation Award Plan and the benefit provided to other similarly situated executives, I am permitted to cash out my vested Employee Units at any time. The value of the units is regularly set by the board. I will receive the most recent valuation. All unvested Verily Award Units will be forfeited upon my resignation from the company.

6/2017

6

Mountain View, California

I will retain the Google, LLC, 401(k) Savings Plan, a defined contribution plan. The plan sponsor will not make further contributions after my separation.

6/2017

1

Cambridge, Massachusetts

Member, Board of Directors; and Member, Nominating & Corporate Governance Committee of the Board of Directors

2

South San Francisco, California

Member, Board of Directors; and Member, Science & Technology Committee of the Board of Directors

3

South San Francisco, California

Senior Advisor

4

Mountain View, California

Senior Advisor (co-employment agreement with Verily Life Sciences, LLC)

5

Durham, North Carolina

Faculty Connection, LLC, arranges for lecture, discussion groups, and consulting services; I received consulting payments through Faculty Connection, LLC

6

Ridgefield, North Carolina

Lecture, discussion groups, and consulting services; received payments through Faculty Connection, LLC

7

Durham, North Carolina

Director, Duke Forge

1

Spouse's IRA

1.1

Acme United Corporation (ACU)

$15,001 - $50,000

None (or less than $201)

1.2

Anika Therapeutics, Inc. (ANIK)

$15,001 - $50,000

None (or less than $201)

1.3

B&G Foods, Inc. (BGS)

$1,001 - $15,000

None (or less than $201)

1.4

Dime Community Bancshares, Inc. (DCOM)

$15,001 - $50,000

None (or less than $201)

1.5

Discovery, Inc. (DISCK)

$1,001 - $15,000

None (or less than $201)

1.6

EnerSys (ENS)

$15,001 - $50,000

None (or less than $201)

1.7

Exelixis, Inc. (EXEL)

$15,001 - $50,000

None (or less than $201)

1.8

Franchise Group, Inc. (FRG)

$15,001 - $50,000

None (or less than $201)

1.9

Greenhill & Co., Inc. (GHL)

$15,001 - $50,000

None (or less than $201)

1

U.S. bank account #1 (cash)

$15,001 - $50,000

None (or less than $201)

2

U.S. bank account #2 (cash)

$15,001 - $50,000

None (or less than $201)

3

U.S. credit union account (cash)

$15,001 - $50,000

None (or less than $201)

4

U.S. brokerage account #1

4.1

JPMorgan Ultra-Short Municipal Income ETF (JMST)

$15,001 - $50,000

$201 - $1,000

4.2

Applied Finance Explorer Fund - Institutional Class (AFDZX)

$100,001 - $250,000

$1,001 - $2,500

4.3

American Funds Investment Co. of America - Class F-3 (FFICX)

$100,001 - $250,000

$5,001 - $15,000

4.4

American Funds New Perspective Fund - Class F-3 (FNPFX)

$15,001 - $50,000

$201 - $1,000

4.5

American Funds Fundamental Investors - Class F-3 (FUNFX)

$50,001 - $100,000

$2,501 - $5,000

4.6

American Funds Washington Mutual Investors Fund - Class F-3 (FWMIX)

$50,001 - $100,000

$5,001 - $15,000

1

1

I have forgone compensation for my position at Bitterroot Bio, Inc.

1

4

I have forgone compensation for my position at Mayo Foundation for Medical Education & Research.

1

11

I have been employed by Duke University since 1980 when I was a clinical fellow, retiring in November 2019 and taking an adjunct professor position. The position renews annually.

1

12

I retired from Duke University in November 2019. However, my position as Donald F. Fortin, M.D. Distinguished Professor of Cardiology did not officially end until December 2019.

1

13

The Duke Center for Health Data Science was renamed as Duke Forge in October 2017.

1

21

My previous position title at Verily Life Sciences, LLC, was Head of Clinical Policy & Strategy until October 1, 2021. My duties for the company have not changed; only my position title changed. As part of my duties with the company, I lead the advisory board of Verily Life Sciences, LLC. I do not hold a separate position or title related to leading this advisory board, and I do not receive any additional compensation for it.

1

22

My previous position title at Google, LLC, was Head of Clinical Policy & Strategy for Google Health until October 1, 2021. My duties for the company have not changed; only my position title changed.

1

25

Subsequent to the submission of this report I resigned from this advisory board position and have not provided any services. I have not received any income for this advisory board position.

2

1

The advisory board fees that were payable by the Medical University of South Carolina to me were donated to charity on my behalf.

2

8

Upon my resignation from Centessa Pharmaceuticals, PLC, acceleration may be allowed for some stock options per company policy.